Do statins increase the risk of developing new‑onset diabetes?

Do Statins Cause Diabetes?

Yes, statins do cause a modest, dose-dependent increase in new-onset diabetes, but the cardiovascular benefits overwhelmingly outweigh this risk and should not deter appropriate statin use. 1

The Evidence on Diabetes Risk

The most comprehensive and recent evidence comes from a 2024 individual participant data meta-analysis of large-scale randomized controlled trials involving over 154,000 participants. This analysis provides definitive clarity:

Magnitude of Risk:

• Low-to-moderate intensity statins: 10% relative increase in new-onset diabetes (RR 1.10,95% CI 1.04-1.16) 1
• High-intensity statins: 36% relative increase in new-onset diabetes (RR 1.36,95% CI 1.25-1.48) 1

Mechanism: The diabetes risk stems from small upward shifts in glycemia markers:

• Mean glucose increases by 0.04 mmol/L with both low/moderate and high-intensity statins 1
• HbA1c increases by 0.06% with low/moderate-intensity and 0.08% with high-intensity statins 1

These are clinically small changes, but they push individuals who are already near the diagnostic threshold over the line into a diabetes diagnosis.

Who Is at Highest Risk?

Approximately 62% of new diabetes cases occur in patients already in the top quartile of baseline glycemia 1. This means:

• Patients with prediabetic glucose levels (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) are most vulnerable
• Those with normal baseline glucose have minimal absolute risk
• The effect persists throughout treatment duration 1

Additional risk factors identified include:

• Older age (≥60 years) 2
• Female gender, particularly in hypertensive women 3
• Longer duration of therapy 2
• Rosuvastatin specifically may carry higher risk 2

Critical Clinical Context: Benefits Far Exceed Risks

The cardiovascular mortality and morbidity reduction from statins vastly outweighs the diabetes risk. This is the most important clinical takeaway. 1

The 2024 meta-analysis explicitly states: "Any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials." 1

In practical terms:

• The cardiovascular benefits (preventing heart attacks, strokes, and death) are captured in the trial outcomes despite the small glycemic increases
• Even in the JUPITER trial (primary prevention in healthy individuals), cardiovascular benefits greatly outweighed diabetes risks 1
• For patients with diabetes at baseline, statins show similar worsening of glycemic control (RR 1.10 for low/moderate intensity, 1.24 for high-intensity) but remain strongly indicated 1

Clinical Management Algorithm

For patients requiring statin therapy:

1. Prescribe the statin - Do not withhold statins due to diabetes concerns in patients who meet cardiovascular risk criteria 1

2. Identify high-risk patients for diabetes monitoring:

   • Baseline HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL
   • Age ≥60 years
   • Women, especially with hypertension
   • Patients requiring high-intensity statins

3. Monitor appropriately:

   • Check baseline HbA1c or fasting glucose before starting statins
   • Recheck at 3-6 months, then annually in high-risk patients
   • For patients who develop diabetes, continue the statin and add diabetes management

4. Dose considerations:

   • Use the statin intensity required for cardiovascular risk reduction
   • Do not reduce intensity solely to avoid diabetes risk
   • The absolute excess diabetes risk is small compared to cardiovascular benefit

Common Pitfalls to Avoid

Do not:

• Withhold statins from patients with prediabetes or diabetes - they benefit equally or more from cardiovascular protection 1, 4
• Discontinue statins if diabetes develops - manage both conditions concurrently
• Use diabetes risk as a reason to avoid high-intensity statins when indicated for high cardiovascular risk
• Attribute all glycemic changes to statins without considering other factors (weight gain from statins is minimal at 0.3 kg and unlikely to explain diabetes risk) 1

Do:

• Counsel patients that small diabetes risk is expected and manageable
• Emphasize that cardiovascular benefits are proven and substantial
• Monitor glycemia in at-risk patients but continue statin therapy
• Follow guideline-directed statin intensity based on cardiovascular risk stratification 4, 5

The evidence is unequivocal: statins cause a modest increase in diabetes diagnoses through small glycemic shifts, but this effect is already factored into their net cardiovascular benefit, which remains strongly positive. 1